| Title |
Gemcitabine for unresectable, locally advanced or metastatic bladder cancer
|
|---|---|
| Published in |
Cochrane database of systematic reviews, April 2011
|
| DOI | 10.1002/14651858.cd008976.pub2 |
| Pubmed ID | |
| Authors |
Mike Shelley, Anne Cleves, Timothy J Wilt, Malcolm Mason |
| Abstract |
The prognosis for unresectable, locally advanced or metastatic transitional cell carcinoma of the bladder is poor with most patients succumbing to their disease within 2 to 3 years. Clinical management at this stage of the disease is palliative with systemic chemotherapy the main treatment of choice. A number of cytotoxic agents have shown activity in metastatic disease including cisplatin, methotrexate, doxorubicin and vinblastine. However, response rates still need improving and toxicities may sometimes be severe, and so the search for newer agents with improved benefit-to-risk ratios is constantly being pursued. One such agent that shows promise is gemcitabine. |
Mendeley readers
The data shown below were compiled from readership statistics for 120 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | <1% |
| Spain | 1 | <1% |
| Switzerland | 1 | <1% |
| Unknown | 117 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 17 | 14% |
| Student > Ph. D. Student | 13 | 11% |
| Student > Bachelor | 13 | 11% |
| Researcher | 8 | 7% |
| Other | 8 | 7% |
| Other | 27 | 23% |
| Unknown | 34 | 28% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 55 | 46% |
| Nursing and Health Professions | 7 | 6% |
| Biochemistry, Genetics and Molecular Biology | 5 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 3% |
| Agricultural and Biological Sciences | 4 | 3% |
| Other | 9 | 8% |
| Unknown | 36 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 April 2011.
All research outputs
#20,143,522
of 22,649,029 outputs
Outputs from Cochrane database of systematic reviews
#11,976
of 12,295 outputs
Outputs of similar age
#101,936
of 108,840 outputs
Outputs of similar age from Cochrane database of systematic reviews
#91
of 94 outputs
Altmetric has tracked 22,649,029 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 12,295 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 30.2. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 108,840 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 94 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.